GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Cyclically Adjusted PB Ratio

Aclaris Therapeutics (FRA:8AT) Cyclically Adjusted PB Ratio : 0.25 (As of Jun. 11, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-11), Aclaris Therapeutics's current share price is €0.9112. Aclaris Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.60. Aclaris Therapeutics's Cyclically Adjusted PB Ratio for today is 0.25.

The historical rank and industry rank for Aclaris Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:8AT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24   Med: 0.3   Max: 0.37
Current: 0.27

During the past years, Aclaris Therapeutics's highest Cyclically Adjusted PB Ratio was 0.37. The lowest was 0.24. And the median was 0.30.

FRA:8AT's Cyclically Adjusted PB Ratio is ranked better than
86.86% of 137 companies
in the Medical Diagnostics & Research industry
Industry Median: 2 vs FRA:8AT: 0.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aclaris Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €1.834. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.60 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aclaris Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Aclaris Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Cyclically Adjusted PB Ratio Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.27

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.27 0.31

Competitive Comparison of Aclaris Therapeutics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PB Ratio falls into.



Aclaris Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aclaris Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.9112/3.6
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aclaris Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aclaris Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.834/131.7762*131.7762
=1.834

Current CPI (Mar. 2024) = 131.7762.

Aclaris Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -1.580 99.070 -2.102
201503 0.000 99.621 0.000
201506 0.496 100.684 0.649
201509 -1.750 100.392 -2.297
201512 4.214 99.792 5.565
201603 3.678 100.470 4.824
201606 3.752 101.688 4.862
201609 3.374 101.861 4.365
201612 6.166 101.863 7.977
201703 5.743 102.862 7.357
201706 5.597 103.349 7.137
201709 6.646 104.136 8.410
201712 6.169 104.011 7.816
201803 5.261 105.290 6.584
201806 4.816 106.317 5.969
201809 4.046 106.507 5.006
201812 4.588 105.998 5.704
201903 3.908 107.251 4.802
201906 2.942 108.070 3.587
201909 1.871 108.329 2.276
201912 1.517 108.420 1.844
202003 1.269 108.902 1.536
202006 1.027 108.767 1.244
202009 0.806 109.815 0.967
202012 0.686 109.897 0.823
202103 1.811 111.754 2.135
202106 3.171 114.631 3.645
202109 3.007 115.734 3.424
202112 2.852 117.630 3.195
202203 2.650 121.301 2.879
202206 3.345 125.017 3.526
202209 3.330 125.227 3.504
202212 2.797 125.222 2.943
202303 2.457 127.348 2.542
202306 2.344 128.729 2.399
202309 2.068 129.860 2.099
202312 2.033 129.419 2.070
202403 1.834 131.776 1.834

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aclaris Therapeutics  (FRA:8AT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aclaris Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (FRA:8AT) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines